Why the study?
Venous thromboembolism is increasingly common, and while treatment evolved with directly acting oral anticoagulants, parenterally administered low-molecular-weight heparins have historically had a wide scope in therapy.
This review discusses the historical significance and current role of low-molecular-weight heparins in treating venous thromboembolism following the introduction of direct oral anticoagulants.
Venous thromboembolism, in the form of lower limb deep vein thrombosis and its most dangerous complication that is a pulmonary embolism, is a common disease with an increasing incidence associated with the ageing population. The scheme of VTE treatment underwent changes when a new drug group — directly and selectively acting oral anticoagulants — was introduced. However, the scope of VTE therapy with parenterally administered low-molecular-weight heparins was wide, i.e., they produced vast progress in the disease’s treatment in the 1980s.
No takes yet. Share an insight, caveat, or question.
Wojtak et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: